Paper17599727
The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest.
Reginster JY. Arthritis Rheum, 2007. Cited by 52 papers, by iCite.
Cite this record
ConductScience Library. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Papers, record 17599727. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17599727
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glucosamine | Major topic |
| Osteoarthritis | Major topic |
| Analgesics | |
| Anti-Inflammatory Agents, Non-Steroidal | |
| Clinical Trials as Topic | |
| Conflict of Interest | |
| Humans | |
| Meta-Analysis as Topic | |
| Reproducibility of Results |
Source PubMed
Comments and corrections3
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 18163480 | Marginal efficacy of glucosamine: comment on the article by VLAD et al and the editorial by Reginster. | https://conductscience.org/library/papers/18163480 | PubMed |
| Comment in | 18163508 | Differing results of trials of glucosamine for pain in arthritis: comment on the article by VLAD et al. | https://conductscience.org/library/papers/18163508 | PubMed |
| Comment on | 17599746 | Glucosamine for pain in osteoarthritis: why do trial results differ? | https://conductscience.org/library/papers/17599746 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 52 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 34189714 | 2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint. | Aging Clin Exp Res | 2021 | https://conductscience.org/library/papers/34189714 | PubMed |
| 33774784 | 2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint. | Aging Clin Exp Res | 2021 | https://conductscience.org/library/papers/33774784 | PubMed |
| 33488785 | Glucosamine sulphate: an umbrella review of health outcomes. | Ther Adv Musculoskelet Dis | 2020 | https://conductscience.org/library/papers/33488785 | PubMed |
| 31073924 | Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. | Drugs Aging | 2019 | https://conductscience.org/library/papers/31073924 | PubMed |
| 30712918 | Type 2 diabetes mellitus and osteoarthritis. | Semin Arthritis Rheum | 2019 | https://conductscience.org/library/papers/30712918 | PubMed |
| 30047014 | Cost Effectiveness of Intra-Articular Hyaluronic Acid and Disease-Modifying Drugs in Knee Osteoarthritis. | Pharmacoeconomics | 2018 | https://conductscience.org/library/papers/30047014 | PubMed |
| 29177637 | Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). | Aging Clin Exp Res | 2018 | https://conductscience.org/library/papers/29177637 | PubMed |
| 26069586 | The Fate of Oral Glucosamine Traced by (13)C Labeling in the Dog. | Cartilage | 2011 | https://conductscience.org/library/papers/26069586 | PubMed |
| 22850875 | Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. | Ther Adv Musculoskelet Dis | 2012 | https://conductscience.org/library/papers/22850875 | PubMed |
| 22461188 | Role of glucosamine in the treatment for osteoarthritis. | Rheumatol Int | 2012 | https://conductscience.org/library/papers/22461188 | PubMed |
| 21826146 | Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids. | Int J Rheumatol | 2011 | https://conductscience.org/library/papers/21826146 | PubMed |
| 21203996 | The role of ADAMTSs in arthritis. | Protein Cell | 2010 | https://conductscience.org/library/papers/21203996 | PubMed |
| 20847017 | Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. | BMJ | 2010 | https://conductscience.org/library/papers/20847017 | PubMed |
| 20238101 | The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). | Osteoporos Int | 2010 | https://conductscience.org/library/papers/20238101 | PubMed |
| 20156334 | Is Phytalgic(R) a goldmine for osteoarthritis patients or is there something fishy about this nutraceutical? A summary of findings and risk-of-bias assessment. | Arthritis Res Ther | 2010 | https://conductscience.org/library/papers/20156334 | PubMed |
| 19087296 | Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. | BMC Musculoskelet Disord | 2008 | https://conductscience.org/library/papers/19087296 | PubMed |
| 18373059 | European regulatory perspectives for innovative therapies. | Osteoporos Int | 2008 | https://conductscience.org/library/papers/18373059 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/17599727
GET https://conductscience.org/api/papers/v1/17599727/authors